Clinical Trial: Phase 1/2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247201) titled 'Phase 1/2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients' on Nov. 19.

Brief Summary: The goal of this clinical trial is to determine if Natural Killer (NK) cell therapy combined with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC) and to identify the highest dose of allogeneic NK cells that is safe and tolerable. Allogeneic NK cells are derived from healthy donors and have been shown to be well tolerated in cancer patients.

The main questions this clinical trial aims to answer are:

1. What is the maximum tolerate...